[EN] TREATMENT OF CARDIOVASCULAR RISK IN DIABETIC PATIENTS<br/>[FR] TRAITEMENT DU RISQUE CARDIOVASCULAIRE CHEZ LES PATIENTS DIABÉTIQUES
申请人:EVOLVA SA
公开号:WO2014106775A2
公开(公告)日:2014-07-10
Disclosed herein are methods of treating cardiovascular risk in diabetic patients using a pharmaceutically acceptable form of (Z)-6-((2S,4S,5R)-2-(2-chlorophenyl)-4-(2- hydroxyphenyl)-1,3-dioxan-5-yl)hex-4-enoic acid in combination with a pharmaceutically acceptable form of a P2Y12 inhibitor.